Drugs / Otilimab
Trials 12 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05304130 | Feb → May 2023 | rheumatoid arthritis | GlaxoSmithKline | Withdrawn | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT03028467 | Jan → Dec 2017 | rheumatoid arthritis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 1/2 | NCT01517282 | Jan 2012 → Jan 2014 | multiple sclerosis | MorphoSys AG | Completed | No outcome recorded |
| Phase 1/2 | NCT01023256 | Dec 2009 → Jun 2012 | rheumatoid arthritis | MorphoSys AG | Completed | No outcome recorded |
| Phase 24 trials | ||||||
| Phase 2 | NCT04376684 | May 2020 → Jul 2021 | severe acute respiratory syndrome | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02799472 | Jun 2016 → Oct 2017 | rheumatoid arthritis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02683785 | Mar 2016 → Nov 2017 | osteoarthritis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 2 | NCT02504671 | Jul 2015 → Dec 2017 | rheumatoid arthritis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT04333147 | May 2020 → Feb 2023 | rheumatoid arthritis | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 3 | NCT04134728 | Oct 2019 → Sep 2021 | rheumatoid arthritis | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT03970837 | Jun 2019 → Oct 2021 | rheumatoid arthritis | GlaxoSmithKline | Terminated | No outcome recorded |
| Phase 3 | NCT03980483 | May 2019 → Sep 2021 | rheumatoid arthritis | GlaxoSmithKline | Completed | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 15 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Otilimab | “We explored the efficacy, safety, and pharmacokinetics of an anti-GM-CSF antibody, otilimab, in patients with hand osteoarthritis.” PMID 38273625 ↗ Sep 20206“Efficacy and Safety of GSK3196165 (Otilimab) Versus Placebo” NCT04134728 ↗ “Biological: GSK3196165 (Otilimab)” NCT03970837 ↗ “GSK3196165 (Otilimab)” NCT03980483 ↗ |
| Known as | GSK3196165 | “Otilimab (GSK3196165)” NCT04333147 ↗ |
| Known as | MOR103 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01023256 ↗ |
| Action | Inhibit | “Several preclinical findings support an anti-GM-CSF therapy for RA.” NCT01023256 ↗1“Granulocyte-macrophage colony-stimulating factor inhibitor” CHEMBL2109433 ↗ |
| Modality | Monoclonal antibody | “MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor” PMID 24534756 ↗ Feb 2014 |
| Route | Intravenous | “trial of intravenous MOR103” PMID 24534756 ↗ Feb 2014 |
| Target | CSF2 | “Granulocyte-macrophage colony-stimulating factor inhibitor” CHEMBL2109433 ↗ |